The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis
Open accessAbstract
Background: Nonalcoholic fatty liver disease (NAFLD) is one of the leading causes of chronic liver disease worldwide with tremendous clinical burden. The economic burden of NAFLD is not well studied. Goal: To assess the economic burden of NAFLD. Study: Medicare beneficiaries (January 1, 2010 to December 31, 2010) with NAFLD diagnosis by International Classification of Diseases, Ninth Revision codes in the absence of other liver diseases were selected. Inpatient and outpatient resource utilization parameters were total charges and total provider payments. NAFLD patients with compensated cirrhosis (CC) were compared with decompensated cirrhosis (DC). Results: A total of 976 inpatients and 4742 outpatients with NAFLD were included—87% were white, 36% male, 30% had cardiovascular disease (CVD) or metabolic syndrome conditions, and 12% had cirrhosis. For inpatients, median total hospital charge was $36,289. NAFLD patients with cirrhosis had higher charges and payments than noncirrhotic NAFLD patients ($61,151 vs. $33,863 and $18,804 vs. $10,146, P<0.001). Compared with CC, NAFLD patients with DC had higher charges and payments (P<0.02). For outpatients, median total charge was $9,011. NAFLD patients with cirrhosis had higher charges and payments than noncirrhotic NAFLD patients ($12,049 vs. $8,830 and $2,586 vs. $1,734, P<0.001). Compared with CC, DC patients had higher total charges ($15,187 vs. $10,379, P=0.04). In multivariate analysis, variables associated with increased inpatient resource utilization were inpatient mortality, DC, and CVD; for outpatients, having CVD, obesity, and hypertension (all P<0.001). Conclusions: NAFLD is associated with significant economic burden to Medicare. Presence of cirrhosis and CVD are associated with increased resource utilization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“once a diagnosis of NAFLD is established patients have increased overall mortality compared to non‐NAFLD patients [6, 21, 22].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Child abuse: Adolescent records vs. adult recall
Femina, D. D., Yeager, C. A., & Lewis, D. O. (1990) · Child Abuse & Neglect · doi:10.1016/0145-2134(90)90033-p · Cited by 8,820
Finkelstein, E. A., Trogdon, J. G., Cohen, J. W., & Dietz, W. (2009) · Health Affairs · doi:10.1377/hlthaff.28.5.w822 · Cited by 2,957 · cited 1×
“0001 Total charge ($) 36,289 (18,359-71,225) 33,863 (17,619-65,238) 61,151 (29,706-124,133) <0.”
Nonalcoholic Fatty Liver Disease: A Systematic Review
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,267 · cited 5×
“Total number of visits 3 (2-4) 1 (1-2) 6 (4-11) 6 (3-11)”
BackgroundInfluentialWilliams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Wong, R. J., Aguilar, M., Cheung, R., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,819
Self-citationObesity and Severe Obesity Forecasts Through 2030
Finkelstein, E. A., Khavjou, O. A., Thompson, H., Trogdon, J. G., Pan, L., Sherry, B., & Dietz, W. (2012) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2011.10.026 · Cited by 1,418 · cited 1×
“0001 Total charge ($) 36,289 (18,359-71,225) 33,863 (17,619-65,238) 61,151 (29,706-124,133) <0.”
Michelotti, G. A., Machado, M. V., & Diehl, A. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.183 · Cited by 974 · cited 3×
“0509 Total payment ($) 11,699 (7167-25,928) 19,767 (12,713-37,787) 0.”
Multiple Chronic Conditions Among US Adults: A 2012 Update
Ward, B. W., Schiller, J. S., & Goodman, R. A. (2014) · Preventing Chronic Disease · doi:10.5888/pcd11.130389 · Cited by 845 · cited 3×
“Total cumulative payment ($) 20,450 (14,949-34,620) 11,043 (6103-21,345) 1400 (611-3183) 1777 (785-4043)”
Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations
Milić, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i28.9330 · Cited by 583 · cited 4×
“34, 430-438 as cerebrovascular disease; (4) diabetes code 250; (5) hypertension codes 401-405; (6) Hyperlipidemia codes 272.”
BackgroundInfluentialAssessing portal hypertension in liver diseases
Berzigotti, A., Seijo, S., Reverter, E., & Bosch, J. (2013) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.12.83 · Cited by 336
Cited by
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
“Patients with NAFLD have increased overall mortality compared to matched control populations without NAFLD.((53,54)) The most common cause of death in patients with NAFLD is cardiovascular disease (CVD), independent of other metabolic comorbidities.”
BackgroundSelf-citationNon-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
“Data from Medicare beneficiaries (2010) were also used to assess the economic burden of NAFLD, based on resource utilisation (total charges and total provider payments) for inpatients and outpatients.(99) The authors found that for inpatients, the median total hospital charge was $36,289.”
BackgroundMethodSelf-citationThe economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Younossi, Z. M., Blissett, D., Blissett, R., Henry, L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R. (2016) · Hepatology · doi:10.1002/hep.28785 · Cited by 1,285
“In a follow-up study of both outpatient and inpatient Medicare resource use, the enormous impact of NAFLD was reiterated and the median total hospital charge for NAFLD patients was $36,289 in 2010.((19)) In the context of growing clinical and quality-of-life burden of NAFLD, the economic burden of this important liver…”
BackgroundMethodSelf-citationYounossi, Z. M., Loomba, R., Anstee, Q. M., Rinella, M. E., Bugianesi, E., Marchesini, G., Neuschwander‐Tetri, B. A., Serfaty, L., Negro, F., Caldwell, S. H., et al. (2018) · Hepatology · doi:10.1002/hep.29721 · Cited by 431
“These data provide strong evidence that the progressive form of NAFLD or NASH, especially those with significant fibrosis, poses tremendous clinical, PRO, and economic burden to individuals and society.((14-20)) This article is the summary of data presented at a recent American Association for the Study of Liver Disea…”
BackgroundSelf-citationCurrent treatment of non‐alcoholic fatty liver disease
Paternostro, R., & Trauner, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13531 · Cited by 305
Metadata
- Authors
- Sayiner, M., Otgonsuren, M., Cable, R., Younossi, I., Afendy, M., Golabi, P., Henry, L., & Younossi, Z. M.
- Affiliations
- Betty and Guy Beatty Center for Integrated Research, Inova Health System
- Inova Health System (US)
- Inova Fairfax Hospital (US)
- Center for Outcomes Research in Liver Diseases (US)
- Corresponding author
- Otgonsuren, Munkhzul
- Golabi, Pegah
- Younossi, Zobair M.
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2017-03
- Volume
- 51
- Issue
- 3
- Pages
- 254-260
- ISSN
- 0192-0790 (ISSN-L)
- PMC
- PMC5300028
- OpenAlex
- W2471504731
- Cited by
- 76
- References
- 32
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 16 · 2019: 11 · 2018: 15 · 2017: 6
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Clinical Gastroenterology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- non-alcoholic fatty liver disease, liver cirrhosis, decompensated cirrhosis, economic burden, healthcare resource utilization, Medicare beneficiaries, hospital charges, provider payment, cardiovascular disease, obesity, hypertension, in-hospital mortality
- MeSH terms
- Aged, Ambulatory Care, Female, Medicare, Health Resources, Hospitalization, Humans, Insurance Benefits, Liver Cirrhosis, Male, United States, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis. https://app.cochat.ai/papers/10.1097/mcg.0000000000000567
- The paper
- Sayiner, M., Otgonsuren, M., Cable, R., Younossi, I., Afendy, M., Golabi, P., Henry, L., & Younossi, Z. M. (2017). Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis. Journal of Clinical Gastroenterology. https://doi.org/10.1097/mcg.0000000000000567
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.